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large (13-18) and extremely large effects (19-30). Severity of disease was 
measured using the Nottingham Eczema Severity scores (NESS). RESULTS: The 
average QOL scores reported were 15.0±6.69 among infants (IDQOL); 16.4±7.25 
among children (CDLQI), and 15.5±7.59 among families (DFI). The mean IDQOL, 
CDLQI and DFI scores were higher in patients with severe AD (16.7±6.66, 
18.4±6.99, and 17.5±7.53, respectively) than among those with moderate AD 
(13.9±6.49, 15.2±7.14, and 14.2±7.35, respectively). A large proportion of 
respondents experienced extremely large effect of QOL scores (scoring 19 to 30), 
including 35.6% of infants, 44.0% of children and 39.1% of families. There were 
also large differences between the reported QOL from different countries. 
CONCLUSIONS: The study found that moderate to severe AD affected the QOL of 
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BACKGROUND: Understanding COPD exacerbation-associated burden, 
particularly in severe (SEV) and very severe (VSEV) patients, can help improve 
medication management. OBJECTIVES: To describe exacerbation frequency, 
treatment, work productivity, and health-related quality of life (HRQoL) for 
patients with SEV/VSEV COPD who recently experienced a moderate (MOD)/SEV 
exacerbation. METHODS: A nationally representative sample of SEV/VSEV COPD 
patients who had experienced a MOD/SEV exacerbation within the past 3 
months was physician recruited. Medical charts were evaluated for patient 
demographic/clinical data, including exacerbation frequency in the previous 12 
months, work productivity and impairment (WPAI), and HRQoL (St. George’s 
Respiratory Questionnaire for COPD, SGRQ-C). RESULTS: This study included 314 
patients (190 SEV/124 VSEV). VSEV (vs. SEV) patients were more likely to be 
Caucasian (93.5% versus 82.1%, P=0.004) and had SEV last exacerbation (44.3% vs. 
29.5%, P=0.016). These 314 patients experienced 829 exacerbations in the 
previous 12 months, of which 556 were MOD (17.2% treated with antibiotics only; 
70.7% with steroids and antibiotics; 12.1% with steroids only), and 273 were SEV 
(19.6% treated in the ER; 53.7% hospitalized with an ER visit; 26.7% hospitalized 
without ER visit). 15.9% of patients (SEV 19.5%/VSEV 10.5%, P=0.033) were 
employed but reported a high percentage of overall work impairment 
(42.4%±31.1%) due to absenteeism/presenteeism. Activity impairment was 
58.7%±28.0% across all patients. SGRQ-C scores (0-100=best-worst health) were: 
Total 64.7±20.4, Symptoms 70.6±19.0, Activities 78.0±21.9, and Impacts 54.7±24.8, 
with total scores being significantly worse for VSEV (vs. SEV COPD; 70.1±21.3 vs. 
61.1±19.0; P<0.001) and SEV last exacerbation (vs. MOD; 70.3±19.9 vs. 61.7±20.1; 
P<0.001). CONCLUSIONS: MOD/SEV exacerbations in SEV/VSEV COPD patients 
impaired patients’ work productivity and were associated with poor HRQoL. 
Since patients with a recent MOD/SEV exacerbation were highly likely to have 
experienced mild/MOD/SEV exacerbations in the previous year, interventions to 
further reduce exacerbations will likely have a strong impact on patient HRQoL.  
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OBJECTIVES: To analyze the effectiveness of a multicomponent home-based 
environmental asthma intervention targeting children from low income families 
in East Harlem, New York City. METHODS: Three hundred eighty children aged 
17 years or younger with asthma participated in the study. These children and 
their families were assessed for baseline characteristics including asthma 
symptoms and health care utilization experienced by a child; presence of home 
environmental triggers; and parents’ knowledge and skills in managing the 
child’s asthma. Based on baseline characteristics, families that received 
environmental intervention (n=200) were compared with those that did not 
(n=18). The main asthma outcomes were rates of emergency department visits 
(edv), hospitalizations (hsp), asthma symptom days (asd), school days missed 
(sdm), and work days missed (wdm) due to asthma. Observable variables 
included age, gender, race, and baseline rates of edv, hsp, asd, sdm, and wdm. 
The effect of the intervention was measured as the difference in the main 
asthma outcomes at the baseline and at post-intervention assessment. To 
reduce the influence of confounding factors we applied propensity score method 
to estimate effect of the intervention on the main asthma outcomes. RESULTS: 
Baseline main asthma outcomes were: 2.56 (intervention group) and 2.64 (control 
group) for edv, 0.44 and 0.62 for hsp, 7.35 and 5.86 for asd, 5.38 and 6.96 for sdm, 
and 6.95 and 3.57 for wdm. The average treatment effect of the intervention was 
2.13 for edv, 0.92 for hsp, 2.67 for asd, 1.95 for sdm, and 1.89 for wdm. All 
estimates, except hospitalizations, were significant. The unmatched outcomes 
for the same outcomes were 3.36, -0.17, 3.80, 1.66, and 1.48 respectively. 
CONCLUSIONS: The results of the study suggest that low-income families can 
benefit from the intervention by reducing emergency department visits, asthma 
symptom days, and missed school and work days.  
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OBJECTIVES: The National Quality Forum (NQF) has endorsed measures from the 
Pharmacy Quality Alliance (PQA) for suboptimal asthma control (SAC) and 
absence of controller therapy (ACT) to measure the quality of care among 
asthma beneficiaries. The purpose of this study was to evaluate a baseline for 
the Mississippi Division of Medicaid using the PQA measures. METHODS: A 
retrospective cross-sectional analysis of 2008-2012 Mississippi Medicaid claims 
was undertaken. Asthma beneficiaries aged 5 - 50 years as of the last day of each 
measurement year were identified. The inclusion and exclusion criteria were 
applied according to the PQA measure specifications, with an expanded age 
inclusion to account for Medicaid’s pediatric population. Beneficiaries with at 
least 3 canisters of short-acting beta agonists within 90 days were identified as 
those with SAC. Of SAC beneficiaries, those who did not receive controller 
therapy including inhaled steroids, long-acting beta agonists, and leukotriene 
inhibitors in the same 90 day period were defined as those with ACT. Costs were 
compared between ACT and non-ACT beneficiaries for each measurement year. 
RESULTS: A total of 62,557 beneficiaries were identified from 2008 to 2012. The 
percentage of asthma beneficiaries having SAC along with ACT decreased from 
8.08% (2008) to 5.15% (2012). Beneficiaries with ACT (compared to non-ACT 
beneficiaries) had significantly higher asthma-related total costs [$1,516.98 vs. 
$593.66 (2008); $1,571.98 versus $648.78 (2009); $1,586.06 versus $664.36 (2010); 
$1,748.73 versus $722.36 (2011); $1,750.64 versus $709.63 (2012)]. Cost differences 
between the two groups for all the years was significant (p<0.01). CONCLUSIONS: 
This study of an expanded SAC/ACT measure in a Medicaid population found 
that the proportion of ACT beneficiaries has consistently decreased since 2008; 
providing a baseline measure for future interventions. Since beneficiaries with 
ACT have higher costs than non-ACT beneficiaries, further decline in the 
numbers for this population is needed in the coming years.  
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OBJECTIVES: Smoking is one of the major risk factors in chronic obstructive 
pulmonary disease (COPD) patients, with 90% of deaths from COPD being 
attributable to smoking. According to the Centers for Disease Control and 
Prevention (CDC), smoking cessation reduces the risk of developing COPD. Still, 
little is known about the use of smoking cessation agents and the factors that 
affect their use among patients. The purpose of the study is to identify the socio-
demographic factors that affect the use of these agents among COPD patients. 
METHODS: A retrospective study was done to identify smokers having COPD 
(ICD9:490-496) and those who use smoking cessation agents from 2006-2010 
using Medical Expenditure Panel Survey (MEPS) data. A multiple logistic 
regression model was built to identify significant socio- demographic predictors 
associated with the use of smoking cessation agents. RESULTS: Out of 2218 
smokers with COPD, 176 reported use of smoking cessation agents during the 5 
year period. Logistic regression showed African Americans were less likely to use 
smoking cessation agents than Caucasians (OR=0.379, 95% CI 0.208-0.688), 
patients having public insurance were more likely to report use of these agents 
than other insurances (OR=2.619, 95% CI 1.265-5.422), and patients with higher 
educational levels (OR=1.127, 95% CI 1.043-1.217) were more likely to use these 
agents. CONCLUSIONS: Results showed that a large number of patients 
continued to smoke even after the diagnosis of COPD whereas; only 176 patients 
(8%) used smoking cessation agents. Race, educational level, and insurance 
status were significant predictors of smoking cessation agents’ use. Further 
research needs to be done to evaluate reasons for minimal use of these agents in 
COPD patients. Results showed inconsistent use of these agents among different 
population groups; hence there is a requirement for need based smoking 
cessation programs.  
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OBJECTIVES: To compare baseline demographics of long-acting beta-agonist 
(LABA) step down in asthma patients taking fluticasone propionate-salmeterol 
via Diskus (FSC). METHODS: A retrospective observational study using pharmacy 
and medical claims data (Market Scan Commercial Database, January 1, 2006 to 
December 31, 2010). Subjects were included if they had : 1) ≥ 2 FSC prescription 
claims prior to the index (step-down) date; 2) ≥ 1 asthma claim [ICD-9-CM] codes 
493.xx); 3) 12-64 years of age; and 4) continuously eligible for 12 months pre and 
post index. Subjects were excluded if they had: 1) COPD diagnosis (ICD-9 codes 
491.xx, 492, xx, 496.xx), or 2) ≥ 1 prescription claim for anti-cholinergics or 3) 
receipt of higher dose FSC or another asthma controller other than FSC or ICS 
after the index. Step-down was defined as reduction in dose of FSC (lower dose 
FSC) or moving to ICS only without the LABA (ICS monotherapy). These two 
cohorts were matched 1:3 with subjects that remained on the starting FSC dose 
